ESMO 2024: Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
ESMO 2024: Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
Despite the recent progress in checkpoint inhibitor therapy, there remains an unmet need to further improve the outcomes of patients with advanced melanoma. Here, we report one-year data from a phase 2 study, assessing safety, efficacy and immunogenicity of the personalized neoantigen (neoAg) peptide vaccine, EVX-01, combined with pembrolizumab in advanced melanoma (NCT05309421). In this study, we identified and selected tumor-specific neoAgs based on tumor DNA- and RNA-sequencing data using the proprietary vaccine target discovery platform, AI-ImmunologyTM.
The top-ranked neoAgs for each patient were manufactured as synthetic long peptides (max. 10 neoAgs) and formulated with a liposomal adjuvant, creating the personalized cancer vaccine, EVX-01, tailored to each patient’s individual tumor and immune system characteristics.
